Status:
COMPLETED
Low-Phosphate Diet and Fibroblast Growth Factor-23 Level
Lead Sponsor:
Wan-Chuan Tsai
Conditions:
Chronic Kidney Disease Requiring Chronic Dialysis
Hyperphosphatemia
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The aims of the study are to evaluate the effect of low-phosphate diet on FGF23 level and to determine the optimal amount of dietary phosphate restriction in hemodialysis patients. In particular, the ...
Detailed Description
In patients with hemodialysis, the prevalence of cardiovascular disease (CVD) is high, and is the leading cause of death. Among several cardiovascular risk factors of hemodialysis patients, elevated f...
Eligibility Criteria
Inclusion
- Subjects with end-stage kidney disease undergoing thrice-weekly hemodialysis for more than three months, the most recent serum phosphate level greater than 5.5 mg/dL or between 3.5 and 5.5 mg/dL with regular phosphate binder use, and having adequate dialysis (urea reduction ratio equal to or greater than 65%)
Exclusion
- Subjects with serum albumin less than 2.5 g/dL, having psychiatric disorders, mental retardation or poor adherence
Key Trial Info
Start Date :
January 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 8 2018
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT03367338
Start Date
January 3 2018
End Date
June 8 2018
Last Update
October 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Far Eastern Memorial Hospital
New Taipei City, Taiwan